The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence

Rheumatoid arthritis (RA) is an immune-mediated inflammatory (autoimmune) rheumatic disease of unknown etiology, which is characterized by chronic erosive arthritis (synovitis) and systemic damage of internal organs and leads to early disability and shorter life expectancy in patients. Much attenti...

Full description

Bibliographic Details
Main Authors:	E. L. Nasonov, A. M. Lila
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2019-11-01
Series:	Научно-практическая ревматология
Subjects:	rheumatoid arthritis interleukin 6 sarilumab
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2780

Similar Items

Inhibitor of biological effects of interleukin-6 sarilumab in treatment of rheumatoid arthritis
by: D. E. Karateev, et al.
Published: (2019-12-01)

New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab
by: D. E. Karateev, et al.
Published: (2019-11-01)

Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
by: Crotti C, et al.
Published: (2018-08-01)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017-05-01)

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
by: Vibeke Strand, et al.
Published: (2020-10-01)

Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study
by: Akira Onishi, et al.
Published: (2025-03-01)

New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
by: Evgeniy L'vovich Nasonov, et al.
Published: (2010-05-01)

Tolerability of Sarilumab – An anti-interleukin-6 receptor monoclonal antibody is controversial for the management of COVID-19
by: Justin Jacob Abraham, et al.
Published: (2021-01-01)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
by: Pelechas E, et al.
Published: (2019-09-01)

Sarilumab use in severe Coronavirus Disease 2019 pneumonia
by: Ahmed M.A. El Fattah Amer, et al.
Published: (2023-01-01)

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
by: Luis Sainz, et al.
Published: (2023-11-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
by: Yoshiya Tanaka, et al.
Published: (2019-03-01)

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts
by: Annett Klinder, et al.
Published: (2022-06-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
by: Andrea Rubbert-Roth, et al.
Published: (2022-08-01)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
by: Vibeke Strand, et al.
Published: (2018-06-01)

Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials
by: Mark C. Genovese, et al.
Published: (2020-09-01)

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
by: Wolfgang A. Schmidt, et al.
Published: (2023-10-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01)

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
by: Thomas Huizinga, et al.
Published: (2023-02-01)

Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19
by: Tatyana S. Kruglova, et al.
Published: (2021-11-01)

Primary pathologic role of interleukin-6 in rheumatoid arthritis
by: G.L. Bajocchi, et al.
Published: (2013-05-01)

Role of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis
by: Elena Vasilyevna Udachkina, et al.
Published: (2013-10-01)

INTERLEUKIN-6 (IL-6) LEVEL AS AN INDIKATOR OF PROGRESIVITY RHEUMATOID ARTHRITIS (RA) DISEASE
by: Putu Oky Ari Tania, et al.
Published: (2017-06-01)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
by: Andrea Marino, et al.
Published: (2022-05-01)

Changes in Iron Metabolism Induced by Anti-Interleukin-6 Receptor Monoclonal Antibody are Associated with an Increased Risk of Infection
by: Renata Ribeiro, et al.
Published: (2019-06-01)

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19
by: N. V. Muravyeva, et al.
Published: (2022-07-01)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
by: Cem Gabay, et al.
Published: (2020-04-01)

Blockade of the interleukin-6 signaling pathway in rheumatoid arthritis: Effects on obesity, adipocytokines and glucose metabolism
by: L. V. Kondratyeva, et al.
Published: (2024-01-01)

Polymyalgia Rheumatica Treated with Sarilumab
by: Anvitha Madhavaram, et al.
Published: (2023-12-01)

Case of successful use of sarilumab in secondary renal amyloidosis in a patient with rheumatoid arthritis
by: L. A. Smirnova, et al.
Published: (2022-11-01)

Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study
by: Alan Kivitz, et al.
Published: (2024-09-01)

The Relationship Between Interleukin-17 and Osteoporosis in Patients with Rheumatoid Arthritis
by: Sedef Akdeniz, et al.
Published: (2018-08-01)

Study of interleukin 33 in rheumatoid arthritis versus osteoarthritis patients
by: Aliaa M. Abd El-Aziz Farag, et al.
Published: (2017-01-01)

interleukin-33 and interleukin-18 serum levels in patients with rheumatoid arthritis and osteoporosis
by: Ali Shahraki, et al.
Published: (2014-05-01)

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
by: Su-Yeon Yu, et al.
Published: (2022-12-01)

Emerging Role of Interleukin-38 (IL-38) in the Development of Rheumatoid Arthritis
by: Shengxiang Liang, et al.
Published: (2024-02-01)

Datasets of YY1 expression in rheumatoid arthritis patients
by: Jinpiao Lin, et al.
Published: (2016-12-01)